Clinical observation of Vonoprazan versus esomeprazole in the treatment of severe reflux esophagitis

doi:10.3877/cma.j.issn.2095-8765.2024.01.002

Abstract

Abstract:

Objective

To compare the clinical efficacy of vonoprazol and esomeprazole in the treatment of severe reflux esophagitis.

Methods

120 patients who were diagnosed severe reflux esophagitis in the gastroenterology department of the People's Hospital of Xinjiang Uygur Autonomous Region from December 2020 to December 2021.Randomly divided into 2 groups, 60 cases in each group, were treated with vonoprazol and esomeprazole respectively, the gastroesophageal reflux disease scale (GERD-Q) score used to evaluate clinical symptoms and effective rate after 4 weeks and 8 weeks of treatment,gastroscopy was re-examined to evaluate mucosal healing after 8 weeks treatment.

Results

The total effective rates of 4-week and 8-week clinical symptom improvement in vonoprazol group were 66.67% and 90.00%, respectively; the 4-week and 8-week clinical symptom improvement rates of esomeprazole group were 63.33%, respectively. 86.67%, and there was no significant difference in the improvement of clinical symptoms between the two groups after treatment (P>0.05). After 8 weeks of treatment, the total effective rates of endoscopic mucosal healing in the vonoprazol group and the esomeprazole group were 90.00% and 88.33%, respectively, and there was no significant difference between the two groups (P>0.05).

Conclusion

Both vonoprazol and esomeprazole can effectively improve the clinical symptoms of severe reflux esophagitis and promote mucosal healing.

Key words: Severe reflux esophagitis, Vonoprazol, Esomeprazole, Symptoms, Endoscopy

Huan He, Wenjie Kong, Feng Gao. Clinical observation of Vonoprazan versus esomeprazole in the treatment of severe reflux esophagitis[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2024, 11(01): 6-10.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2024.01.002

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2024/V11/I01/6

Figures/Tables 4

References 37

1	El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review[J]. Gut, 2014, 63(6): 871-880.
2	Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis[J]. Aliment Pharmacol Ther, 2001, 15(2): 227-231.
3	Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1452-1458.
4	Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study[J]. Am J Gastroenterol, 2004, 98(12): 2616-2620.
5	Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study[J].Scand J Gastroenterol, 2007, 42(2): 157-164.
6	中华医学会消化病学分会. 2020年中国胃食管反流病专家共识[J].中华消化杂志, 2010, 40(10): 649-663.
7	李兆申, 王雯, 许国铭, 等.反流性食管炎1827例临床分析[J].中华内科杂志, 2001, 40(1):9-12.
8	Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease:best practice advice from the clinical guidelines committee of the American College of Physicians[J]. Ann Intern Med, 2012, 157(11): 808-816．
9	Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population[J]. J Gastroenterol, 2009, 44(6): 518-534.
10	Richter JE. How to manage refractory GERD[J]. Nat Clin Pract Gastroentero Hepatol, 2007, 4(12): 658-664．
11	Dent J, Vakil N, Jones R, et al.Accuracy of the diagnosis of GERD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study[J]. Gut, 2010, 59(6): 714-721.
12	Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole clinical research group[J]. Aliment Pharmacol Ther, 1995, 9(2): 145-151.
13	Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group[J]. Am J Gastroenterol, 1996, 91(9): 1749-1757.
14	Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis[J]. Aliment Pharmacol Ther, 2001, 15(2): 227-231.
15	Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1452-1458.
16	Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study[J]. Am J Gastroenterol, 2004, 98(12): 2616-2620.
17	Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study[J].Scand J Gastroenterol, 2007, 42(2): 157-164.
18	Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis[J]. World J Gastroenterol, 2009, 15(8): 990-995.
19	Umegaki E, Iwakiri K, Hiramatsu N, et al. Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to Lansoprazole (15 mg Once-Daily) in a 24-week maintenance treatment for healed erosive esophagitis[J]. Gastroenterology, 2014, 146(5): 738-741.
20	Malfertheiner P, Lind T, Willich S, et al.Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study[J].Gut, 2005, 54(6): 746-751.
21	Lichtenstein DR, Cash BD, Davila R, et al. Role of endoscopy in the management of GERD[J]. Gastrointest Endosc, 2007, 66(2): 219-224.
22	Higuchi K, Joh T, Nakada K, et al. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients[J]. Intern Med, 2013, 52(13): 1447-1454.
23	Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study[J]. Aliment Pharmacol Ther, 2015, 42(6): 719-730.
24	Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2015, 41(7): 636–648.
25	Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis[J]. Aliment Pharmacol Ther, 2019, 49(2): 140-146.
26	Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase Ⅲ, randomized, double-blind, placebo-controlled, multicenter study[J]. Curr Ther Res Clin Exp, 2016,81-82:1-7.
27	Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study[J]. Clin Transl Gastroenterol, 2019, 10(11), 1-9.
28	Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis[J]. Aliment Pharmacol Ther, 2016, 43(2): 240-251.
29	Hershcovici T, Fass R. Nonerosive reflux disease (NERD) -an update[J]. J Neurogastroenterol Motil, 2010, 16(1): 8-21.
30	Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2015, 41(7): 636-648.
31	Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease?[J]. Clin Transl Gastroenterol, 2015, 6(10): e119.
32	Hiramatsu N, Kudou K, Umegaki, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis[J].Aliment Pharmacol Ther, 2015, 42(6): 685-695.
33	Xiao Y, Zhang S, Dai N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut, 2019, 69(2): 318-365.
34	Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 2010, 32(1): 29-42.
35	Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-ompetitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis[J]. Aliment Pharmacol Ther, 2019, 49(7): 864-872.
36	Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021[J]. J Gastroenterol, 2022, 57(4): 267-285.
37	Olbe L, Lundell L. Medical treatment of reflflux esophagitis[J]. Hepatogastroenterology, 1992, 39(4): 322-324.

1周内症状发生的频率	0 d	1 d	2~3 d	4~7 d
烧心	0	1	2	3
反流	0	1	2	3
上腹部中央疼痛	3	2	1	0
恶心症状	3	2	1	0
因烧心或反流影响睡眠	0	1	2	3
额外自行服用药物来缓解烧心和（或）反流	0	1	2	3

1周内症状发生的频率	0 d	1 d	2~3 d	4~7 d
烧心	0	1	2	3
反流	0	1	2	3
上腹部中央疼痛	3	2	1	0
恶心症状	3	2	1	0
因烧心或反流影响睡眠	0	1	2	3
额外自行服用药物来缓解烧心和（或）反流	0	1	2	3

组别	例数	年龄（岁，）	性别（例）		LA分级（例）		食管裂孔疝（例）
组别	例数	年龄（岁，）	男性	女性	LA-C级	LA-D级	食管裂孔疝（例）
伏诺拉生组	60	55.41 ±13.52	38	22	42	18	27
艾司奥美拉唑组	60	56.23 ±14.73	44	16	45	15	26

组别	例数	年龄（岁，）	性别（例）		LA分级（例）		食管裂孔疝（例）
组别	例数	年龄（岁，）	男性	女性	LA-C级	LA-D级	食管裂孔疝（例）
伏诺拉生组	60	55.41 ±13.52	38	22	42	18	27
艾司奥美拉唑组	60	56.23 ±14.73	44	16	45	15	26

[1]	Yuanyuan He, Jia Li, Hong Yang. Mesonephric adenocarcinoma of uterine cervix: a case report and literature review [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(01): 97-104.
[2]	Zhiwei Hu, Jimin Wu, Zhonghao Wang, Meiguang Zhang. Selection of indications and preoperative evaluation of anti-reflux surgery for extraesophageal symptoms of gastroesophageal reflux disease [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(03): 241-246.
[3]	Dongao Wang, Chao Lin, Changyong E. Causes, diagnosis and treatment of postoperative pancreatic hemorrhage [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 472-480.
[4]	Weichuan Dai, Xieli Guo, Zhongning Fang, Wenhua Cai, Tiansheng Hong, Xiayang Tian. Clinical efficacy of peripheral nerve release under microscope in the treatment of residual neurological symptoms after lumbar disc herniation [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2024, 10(02): 84-90.
[5]	Li Hu, Shilong Wei, Zhenbo Gang, Chuncheng Xie. Total endoscopic trigeminal microvascular decompression for trigeminal neuralgia [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2024, 14(03): 190-192.
[6]	Jun Zhou, Zhiming Zhao, Yunfeng Liu, Zhaowei Tang, Changhua Song, Jie Liu, Haoran Li, Shaoguang Wu. Efficacy analysis of neuroendoscopic hematoma evacuation and external ventricular drainage in the treatment of intraventricular hemorrhage [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2024, 14(02): 86-92.
[7]	Shuang Ren, Yiying Liu, Yang Li. Clinical effect of rebamipide combined with esomeprazole in the treatment of erosive gastritis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 249-252.
[8]	Jian Chen, Zihao Zhang, Yongda Lu, Kaijian Xia, Ganhong Wang, Luojie Liu, Xiaodan Xu. Construction of automatic classification model for colorectal polyp diagnosis based on deep learning [J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(01): 9-17.
[9]	Chenyi Zhao, Bo Ning, Hao Dong, Xiuxue Feng, Huikai Li, Ningli Chai, Enqiang Linghu. Research and development progress of disposable gastrointestinal endoscopy [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(02): 116-119.
[10]	Zixin Wang, Ningli Chai, Enqiang Linghu. Research progress in the early diagnosis of esophageal cancer by chromoendoscopy [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(02): 123-126.
[11]	Xiaohuan Yu, Lu Lu, Lu Liu, Yichao Yang, Zhenfeng Zhao, Ge Ye, Ying Xiong. Comparison of colorectal adenomas detected by LCI and NBI [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(01): 13-17.
[12]	Chenyue Hu, Xianxiu Ge, Xueting Deng, Jianan Yao, Lin Miao. Diagnosis of early gastric cancer and precancerous lesions by magnifying image-enhanced endoscopy [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(01): 47-51.
[13]	Xuejian Wang, Zhifeng Wang, Ming Qian, Lei Jiang, Xiaowei Song, Weiliang Hu. Comparison of efficacies between neuroendoscopy and trepanation and drainage on chronic subdural hematoma: a meta-analysis [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2024, 10(02): 65-69.
[14]	Yongbin Wang, Yanxun Jia, Yiguang Yin. Effect of neuronavigation combined with 3D reconstruction technique guided neuroendoscopic hematoma removal on patients with hypertensive intracerebral hemorrhage [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(02): 153-156.
[15]	Zhiyu Zhang, Yuehong Pei, Ling Yu, Jun Wang, Yu Fu. Clinical phenotype and potential physiological mechanism of prodromal symptoms of migraine [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(01): 64-70.

Please choose a citation manager

Content to export